The nation of Zimbabwe has declined a substantial American health deal worth $367m (272 million pounds) over five years due to the United States' insistence on sensitive information.
This rejection became public following a government memo dated December was disclosed, which showed President Emmerson Mnangagwa felt the agreement was "skewed".
A government spokesman has since clarified that the US was demanding access to health data for research and commercial gain while was unwilling to guarantee the benefits from future vaccines.
"We are forced to start the challenging and unfortunate process of scaling back our support in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy said the United States had donated over $1.9bn in health funding to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has called for continued talks to find a agreement suitable to both sides so the country's critical HIV treatment initiative can continue.
Wider Context
This development comes after a similar situation in Kenya, where a high court blocked a related health funding agreement after legal challenges were filed about the security of citizens' health data.
Since returning to office recently, US President Donald Trump has reduced foreign aid and closed the key foreign aid agency.
The agency had managed assistance for the US government, but Trump stated its spending was "inefficient" and his administration was seeking government-to-government agreements to enhance openness and responsibility.
As per reports, Sixteen nations in Africa have so far signed similar health pacts, constituting more than $18.3bn of fresh investment.
Specifics of the Declined Deal
The funds for Zimbabwe was intended to gone towards "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this cooperation could have provided extraordinary advantages for Zimbabwean communities, especially the 1.2 million presently receiving HIV treatment via US-supported initiatives," the Ambassador commented.
However, official spokesman Nick Mangwana argued the proposed deal was "unfair".
"The proposal required Zimbabwe to provide its biological resources and data for a long time, without any equivalent promise of access to any scientific breakthroughs – like new medicines or tests – that could result from that shared data," Mangwana explained.
"In essence, our country would provide the raw materials for medical research with no certainty that the end products would be accessible to our people if a new pandemic emerge."
Sovereignty and International Frameworks
Mangwana further pointed out that the US's withdrawal from the World Health Organization (WHO) and its push of bilateral health agreements were undermining systems previously established through the global health agency.
The spokesperson cited its Pathogen Access and Benefit Sharing system designed to deal with future global health emergencies.
"This mechanism is intended to guarantee that when a country provides its information, the benefits – including medicines and cures – are distributed fairly, not commercialised solely by those with the funds to develop them."
These objections regarding the US deal "should not be misconstrued as opposition to America," he added.
"We encourage ongoing dialogue with our US partners on how subsequent co-operation might be designed in a way that honours the sovereignty and dignity of both nations."
Health Experts Response
A leading public health body stated it acknowledged the official position, but recommended that negotiations should continue given that much of the country's Aids initiatives relied on external financing.
"In cases where specific concerns exist, including those relating to information security or agreement terms, these can frequently be addressed through detailed discussion and negotiated safeguards," the group said.
The halted deal emphasises the complex challenges between receiving vital international aid and protecting local interests in an ever more data-driven world.